The CHS/Pfizer Care until Cure Research Program
Funds Canadian research to advance clinical and psychosocial understanding and care for people with inherited bleeding disorders, including hemophilia and related conditions.
Funder: Canadian Hemophilia Society
Due Dates: November 29, 2024 | November 28, 2025 | November 28, 2026
Funding Amounts: Up to $75,000/year (max $150,000 over 2–3 years per project); annual disbursement.
Summary: Supports Canadian research on medical and psychosocial aspects of bleeding disorders to improve patient outcomes and quality of life.
Key Information: Applications must be submitted online; grants are for Canadian researchers/institutions only.
Description
The CHS/Pfizer Care until Cure Research Program, established by the Canadian Hemophilia Society in partnership with Pfizer Canada, funds clinical and psychosocial research relevant to inherited bleeding disorders. The program aims to advance understanding and care for individuals with hemophilia, von Willebrand disease, other inherited bleeding disorders, carriers, and those with related conditions such as HIV or hepatitis C. Areas of interest include epidemiology, outcome research, real-world data, personalized treatment, clinical monitoring, gene therapy, TFPI/anti-TFPI monoclonal antibodies, and antifibrinolytic therapy. Projects are expected to contribute to improving the health and quality of life of affected individuals, with research conducted by Canadian investigators affiliated with Canadian universities or not-for-profit health-related organizations.
